Jaguar Health, (JAGX) announced the results of the special meeting of Jaguar stockholders held on December 9, 2020. As previously announced, the meeting was adjourned to December 22, 2020.
The Company’s stockholders approved two proposals at the Special Meeting. On November 6, 2020, the Company filed a definitive proxy statement regarding the Special Meeting on Schedule 14A with the SEC. A free copy of Jaguar’s proxy statement and other SEC filings is available on Jaguar’s corporate website (https://www.sec.gov).
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
As revealed last week, Jaguar Health, (JAGX) finished a road show with the Swiss Development Forum, a sponsor of Post Pandemic Recovery Equity, a European special purpose acquisition firm. The Business expects to create Napo EU, a subsidiary in Europe focused on the production of crofelemer for diarrhoea associated with ‘long-hauler’ post-COVID-19 recovery patient syndrome, in order to achieve a possible merger with SPAC, which intends to invest between EUR 20 million and EUR 50 million. Napo EU will be licenced exclusively to Crofelemer for Europe, the company’s latest patented medicinal medicine, which will be needed to produce crofelemer for inflammatory diarrhoea and HIV-related diarrhoea indications.
The Swiss Development Forum is holding an investor webinar on Napo EU and SPAC on Wednesday 23 December at 10:30 AM Eastern. By clicking here, investors wanting to take part in the webinar are encouraged to participate.